沙库巴曲缬沙坦在心衰治疗中的应用:从临床试验到真实世界  

Application of sacubitril/valsartan in the treatment of heart failure:from clinical trial to the real world

作　　者：陈文文[1] 刘燕琳[1] 李振山[1] 尹玲[1] 耿涛[1] 党和勤[1] CHEN Wen-wen;LIU Yan-lin;LI Zhen-shan;YIN Ling;GENG Tao;DANG He-qin(Department of Pharmacy,Affiliated Hospital of Taishan Medical University,Shandong Tai＇an 271000,China)

机构地区：[1]泰山医学院附属医院药剂科,山东泰安271000

出　　处：《中国医院药学杂志》2018年第21期2286-2290,共5页Chinese Journal of Hospital Pharmacy

基　　金：泰山医学院附属医院青年基金(编号:2014QN05)

摘　　要：传统心衰药物治疗方案在一定程度上可改善患者心衰症状,但无法有效降低患者死亡率及因心衰住院率,因此开发新型心衰治疗药物迫在眉睫。2015年,具有双重作用机制的血管紧张素受体脑啡肽酶抑制剂(angiotensin receptor neprilysin enzyme inhibitor,ARNI)沙库巴曲缬沙坦被美国食品药品监督管理局(the Food and Drug Administration,FDA)批准上市,为心衰患者的治疗带来了新的希望。本文综述了沙库巴曲缬沙坦的药学性质,更新了相关临床试验结果,并介绍其在真实世界中的应用效果,以期为临床心衰药物治疗提供参考。Traditional therapeutic drugs for heart failure（HF）could effectively improve patients’ symptoms,however,the risks of death and hospitalization due to heart failure remained high.Thus,developing novel drugs for HF was on the agenda imminently.In 2015,sacubitril/valsartan which had a dual action mechanism was approved by FDA as the first angiotensin receptor neprilysin enzyme inhibitor（ARNI）,bringing another therapeutic option for patients with HF.This article reviewed the pharmaceutical properties of sacubitril/valsartan,updated the data of clinical trials,and introduced its application in the real world,to provide a reference for clinical HF therapy.

关 键 词：心衰 血管紧张素受体脑啡肽酶抑制剂 沙库巴曲缬沙坦 

分 类 号：R972[医药卫生—药品]